BNET Industries
Last Fiscal Year Sales:$40.4M
- Private
- US
Dow Jones Description
Perlegen Sciences, Inc., is working to provide safe and effective medicines to patients worldwide. The company quickly and cost effectively analyzes more than one million genetic variations in clinical trial participants to explain and predict the efficacy and adverse effect profiles of prescription drugs. Perlegen also applies this expertise to discovering genetic variants associated with disease in order to pave the way for new therapeutics and diagnostics. For years, scientists and drug manufacturers have been eager to comprehensively examine entire genomes; through Perlegen, their moment has come. Perlegen is able to bring drugs to the market whose clinical development would have been otherwise discontinued.
Number of Employees 105
Contact Information
2021 Stierlin Ct
Mountain View, California 94043-4655
(650) 625-4500
Peer Companies
NAICS Code Research and Development in the Social Sciences and Humanities: 541720
Recent Events
-
Perlegen Releases BREVAGen Breast Cancer Risk Stratification Test
News & Analysis
Filter by
perlegen sciences inc. - All News and Analysis
Perlegen Lab Receives CLIA License
- 2009-06-04
Lab Will Support MammaPLUS Launch Set for Fall 2009 MOUNTAIN VIEW, Calif. -- Perlegen Sciences, which develops genetic tests that correlate genetic variation to disease...
Perlegen Builds Commercial Group to Support Upcoming MammaPLUSâ?¢ Launch
- 2009-04-28
Industry Veterans Will Introduce Breast Cancer Risk Stratifier to Help Physicians Determine Monitoring and Treatment Plans for Women with Intermediate Levels of Risk ...
Perlegen Out-Licenses Genetic Diagnostics Intellectual Property to Celera
- 2009-04-23
Genetic Analysis Patents and Cardiac Genetic Markers Key to Development of New Celera Tests MOUNTAIN VIEW, Calif. -- Perlegen Sciences, which develops genetic tests that...
Perlegen Sciences Out-Licenses Intellectual Property for Genetic Diagnostics
- 2008-07-15
Patent Family Comprises Complementary Technologies That Enable Predictive Whole Genome Association Studies MOUNTAIN VIEW, Calif. -- Perlegen Sciences, Inc., a molecular diagnostics company focused on the discovery and commercialization of clinically important human genetic variation, announced today the opening of its portfolio of patented technologies that together enable whole...
Perlegen Gains Exclusive Access to Data on Four Million Patients to Enable Personalized Medicine
- 2008-03-18
MOUNTAIN VIEW, Calif. -- Perlegen Sciences, Inc. announced today that it has formed a personalized medicine collaboration with an undisclosed electronic medical records EMR provider to identify and develop genetic markers to help predict how patients are likely to respond to specific medical treatments. Perlegen and its partner will mine...
Perlegen and SC Liver Research Consortium to Collaborate on Interferon Response in Hepatitis C Patients
- 2008-02-19
MOUNTAIN VIEW, Calif. & SAN DIEGO -- Perlegen Sciences, Inc., and the SC Liver Research Consortium SCLRC, announced today a collaboration to discover genetic variations that predict which patients with hepatitis C HCV are most likely to benefit from treatment. The parties will conduct large scale genetic studies on samples...
Perlegen Bolsters Leadership Team
- 2008-02-18
Wireless News 02-18-2008 Perlegen Bolsters Leadership Team WIRELESS NEWS-February 18, 2008-Perlegen Bolsters Leadership Team C2008 10Meters - http://www.10meters.com Perlegen Sciences announced the recruitment of three senior professionals to help position the company to execute an upcoming pipeline of genetic, drug...
Perlegen Fills out Leadership Team to Prepare for Multiple Personalized Medicine Programs
- 2008-02-14
MOUNTAIN VIEW, Calif. -- Perlegen Sciences announced today the successful recruitment of three senior professionals to help position the company to execute an upcoming pipeline of genetic, drug response studies. A leader in discovering and understanding the role that human genetic variation plays in patients' response to drugs, Perlegen applies...
Perlegen Expands Leadership Team to Prepare For Landmark Personalized Medicine Programs
- 2007-10-31
MOUNTAIN VIEW, Calif. -- Perlegen Sciences announced today the successful recruitment of three senior professionals to help the company prepare for several key landmark drug response studies. Patient identification and DNA collection is already underway for the initial study, with additional sample collections scheduled to commence before year end. ...
Perlegen's Contribution to Phase 2 HapMap of Human Genetic Variation Empowers Scientists Studying Common Diseases
- 2007-10-17
MOUNTAIN VIEW, Calif. -- The six-country International HapMap Consortium today made available to the public its second-generation map of human genetic variation. This new map contains three times the number of markers unveiled in the initial version, released in 2005. The Consortium noted that this unprecedented research tool "relied...
Industry Transcripts by Seeking Alpha
-
Accenture Ltd. F1Q10 (Qtr End 11/30/09) Earnings Call Transcript
on Dec 17, 2009about ACN
-
FedEx F2Q10 (Qtr End 11/30/09) Earnings Call Transcript
on Dec 17, 2009about FDX
-
Fifth Street Finance Corp. F4Q09 (Qtr End 09/30/09) Earnings Call Transcript
on Dec 10, 2009about FSC
-
SAIC, Inc. F3Q10 (Qtr End 10/31/09) Earnings Call Transcript
on Dec 08, 2009about SAI
-
Casella Waste Systems Inc. F2Q10 (Qtr End 10/31/09) Earnings Call Transcript
on Dec 03, 2009about CWST
IndustryTop Rated
- Google Offers Free Downloads of a Million Books 11 votes
- InsideView Disrupts Legacy Business Info Publishers Like Hoover's 9 votes
- Mobile is the New Mass Medium, For Better or Worse 8 votes
- As Income Mobility Falls, American Dream Fades 7 votes
- Predictions for 2010 Worth Listening to, from Craig, Jimmy and Alec 6 votes
Presented by American Express